Xconomy | Seattle - Business + Technology in the Exponential Economy

Stem Cell Entrepreneur Quinn Dies, Dendreon Tames Shorts, PhysioSonics Monitors Brain Blood, & More Seattle-Area Life Sciences News
OncoGenex Raises $9.5M
The Northwest Biotech Survival Index 2: Companies Scraping By in Downturn
Ventures West Cashes Out Stake in OncoGenex, Developer of Prostate Cancer Drug
ZymoGenetics Picks Up Mojo, Dendreon Looks Southeast, Cell Therapeutics Raises Dough & More Seattle-Area Life Sciences News

CTI, OncoGenex Join Russell Indexes

Cell Therapeutics (NASDAQ: CTIC) and OncoGenex Pharmaceuticals (NASDAQ: OGXI), a pair of Seattle-area cancer drug developers, were added to several stock indexes compiled by Russell Investments. Both companies joined the Russell 3000 Index, which measures the performance of the 3,000 largest U.S. public companies. The Russell indexes are widely used for index funds, and as benchmarks for actively managed funds.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: